![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Parand Darou Pharma](https://www.pharmacompass.com/image/flap/parand-darou-desktop-headergif-12950.gif)
![Parand Darou Pharma](https://www.pharmacompass.com/image/flap/parand-darou-mobgif-20656.gif)
Active Filter(s):
Details:
The phase 3 study enrolled 103 patients and is assessing the safety and efficacy of isavuconazole in adult Japanese patients suffering from deep-seated mycoses, including invasive aspergillosis and mucormycosis.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Basilea Pharmaceutica
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021